Stockscreener 앱 받기
14.48
5.97%
-0.92
시간 외 거래:
14.60
0.12
+0.83%
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
Summit Therapeutics (SMMT) Analyst Rating Update: January 30, 20 - GuruFocus
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA By Investing.com - Investing.com Canada
US regulator accepts Summit filing for ivonescimab combo - The Pharma Letter
Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway - Benzinga
Aug Gainers: Is Summit Therapeutics Inc impacted by rising rates2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Summit Therapeutics (SMMT) Advances with FDA Filing for Cancer T - GuruFocus
Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab - marketscreener.com
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Dr - GuruFocus
Summit Therapeutics’ Ivonescimab BLA Accepted by FDA - TipRanks
Summit spikes as lead asset gets FDA review (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics Inc FDA Accepts Ivonescimab BLA for NSCLC Treatment - TradingView
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug - Investing.com
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab - StreetInsider
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Yahoo Finance
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive - Finviz
Aug Retail: Can Summit Therapeutics Inc be the next market leaderPortfolio Risk Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Trading the Move, Not the Narrative: (SMMT) Edition - Stock Traders Daily
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 100.75% Potential Upside in Biotech Investment - DirectorsTalk Interviews
Breakout Move: What is Summit Therapeutics Inc.’s TAM (Total Addressable Market)Options Play & Long-Term Safe Investment Ideas - mfd.ru
Will Ivonescimab’s FDA Filing and GSK Combo Trial Redefine Summit Therapeutics’ (SMMT) Core Narrative? - Sahm
Summit Therapeutics (NASDAQ:SMMT) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Nasdaq Index Biotech Research - Kalkine Media
Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? - Benzinga
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation - MSN
(SMMT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Is Summit Therapeutics (SMMT) Building a Durable Oncology Combination Platform With Ivonescimab’s Expanding Reach? - Sahm
Buyout Rumor: Will Summit Therapeutics Inc outperform the market in YEAR2025 Major Catalysts & Long-Term Growth Stock Strategies - baoquankhu1.vn
Summit Therapeutics Advances Ivonescimab Into Key Phase 3 Test in Metastatic Colorectal Cancer - TipRanks
Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Trial Collaboration - Sahm
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Summit Therapeutics PLC $SMMT Shares Purchased by APEIRON CAPITAL Ltd - MarketBeat
Summit Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Can Summit Therapeutics Inc. be the next market leaderBull Market Opportunities & Breakout Portfolio Performance - bollywoodhelpline.com
Rate Cut: Will Summit Therapeutics Inc benefit from AI trends2025 Macro Impact & Weekly Return Optimization Alerts - baoquankhu1.vn
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge - Yahoo Finance
Citizens reiterates Market Outperform rating on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 13.4%What's Next? - MarketBeat
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows - TechStock²
2 Biotech Stocks That Could Soar This Year - The Globe and Mail
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC - Business Wire
GSK Collaborates with Summit Therapeutics on Cancer Treatment Tr - GuruFocus
Summit Therapeutics Files Marketing Application for Lung Cancer Therapy - 富途牛牛
Summit Therapeutics (SMMT) Seeks FDA Approval for Innovative Lun - GuruFocus
Summit Therapeutics partners with GSK for cancer drug combination trial - StreetInsider
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) - Business Wire
Summit Therapeutics files FDA application for cancer drug ivonescimab - StreetInsider
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Cantor Fitzgerald reaffirms overweight rating on Summit Therapeutics (SMMT) before key 2026 catalyst - MSN
1.27%
자본화:
|
볼륨(24시간):